(Q79103495)

English

High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer

scientific article published on November 20, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

10.1002/IJC.11420

https://api.crossref.org/works/10.1002/IJC.11420

16 March 2024

Pär-Ola Bendahl

2

object named as

Pär-Ola Bendahl

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Christer Borgfeldt

1

object named as

Christer Borgfeldt

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520707

16 March 2024

author name string

Barbro Gustavsson

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Eva Långström

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Mårten Fernö

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Roger Willén

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Seija Grenman

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Bertil Casslén

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

language of work or name

0 references

publication date

1 November 2003

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

20 November 2003

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14520707

16 March 2024

number of pages

8

1 reference

based on heuristic

inferred from page(s)

full work available at URL

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.11420

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14520707

16 March 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fijc.11420

1 reference

10.1002/IJC.11420

https://api.crossref.org/works/10.1002/IJC.11420

16 March 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.11420

1 reference

10.1002/IJC.11420

https://api.crossref.org/works/10.1002/IJC.11420

16 March 2024

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

107

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

658-665

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

The plasminogen activation system in tumor growth, invasion, and metastasis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

The urokinase-type plasminogen activator system in cancer metastasis: a review

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Plasminogen activator inhibitor type 2 in breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

The plasminogen-activation system in ovarian tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Plasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1)

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Cell-surface acceleration of urokinase-catalyzed receptor cleavage

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Low density lipoprotein (LDL) receptor-related protein 1B impairs urokinase receptor regeneration on the cell surface and inhibits cell migration

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

MAP kinase cascade signaling and endocytic trafficking: a marriage of convenience?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

Human endothelial cell migration is stimulated by urokinase plasminogen activator:plasminogen activator inhibitor 1 complex released from endometrial stromal cells stimulated with transforming growth factor beta1; possible mechanism for paracrine st

1 reference

https://api.crossref.org/works/10.1002%2FIJC.11420

21 January 2018

The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients

10

1 reference

10.1002/IJC.11420

https://api.crossref.org/works/10.1002/IJC.11420

16 March 2024

Biology and biochemistry of proteinases in tumor invasion.

12

1 reference

10.1002/IJC.11420

https://api.crossref.org/works/10.1002/IJC.11420

16 March 2024

Improved medium for extraction of plasminogen activator from tissue

19

1 reference

10.1002/IJC.11420

https://api.crossref.org/works/10.1002/IJC.11420

16 March 2024

Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis

56

1 reference

10.1002/IJC.11420

https://api.crossref.org/works/10.1002/IJC.11420

16 March 2024

Identifiers

10.1002/IJC.11420

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14520707%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q79103495&oldid=2103362412"